ZMYM3

Across TCGA pan-cancer cohorts, ZMYM3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZMYM3 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZMYM3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZMYM3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where ZMYM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.260	0.547	.006	18	view →
LUAD	OS	Median	III,IV	0.775	0.219	.003	10	view →
UCEC	DFS	Median	All	0.836	0.964	.009	2	view →
LSCC	DFS	Median	II,III,IV	0.861	0.693	.035	1	view →
CCRCC	OS	Median	II,III,IV	0.554	1.000	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZMYM3–PDAC (DFS)

Open the PDAC breakdown →